Sunitinib malate for the treatment of pancreas malignancies – where does it fit?
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Sunitinib malate for the treatment of pancreas malignancies – where does it fit?
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume 14, Issue 6, Pages 783-792
Publisher
Informa Healthcare
Online
2013-03-05
DOI
10.1517/14656566.2013.776540
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors: Preliminary results
- (2017) P. L. Kunz et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors
- (2017) A. P. Venook et al. JOURNAL OF CLINICAL ONCOLOGY
- Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).
- (2017) E. Raymond et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-initiated angiogenesis and the uPA/uPAR system
- (2013) Johannes M. Breuss et al. Cell Adhesion & Migration
- Contrasting effects of sunitinib within in vivo models of metastasis
- (2012) Jonathan C. Welti et al. ANGIOGENESIS
- A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors
- (2012) J. R. Strosberg et al. ANNALS OF ONCOLOGY
- A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors
- (2012) Diane L. Reidy-Lagunes et al. CANCER
- Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): A critical view
- (2012) Nicola Fazio et al. CANCER TREATMENT REVIEWS
- Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors
- (2012) Jennifer A. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Sunitinib in pancreatic neuroendocrine tumors
- (2012) Eric Raymond et al. Targeted Oncology
- Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas
- (2012) Ingrid H. Olsen et al. TheScientificWorldJOURNAL
- Hypertension as predictor of sunitinib treatment outcome in metastatic renal cell carcinoma
- (2011) Petri Bono et al. ACTA ONCOLOGICA
- Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma
- (2011) Hedia Brixi-Benmansour et al. DIGESTIVE AND LIVER DISEASE
- The role of pericytes in angiogenesis
- (2011) Domenico Ribatti et al. INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
- (2011) Eric Raymond et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
- (2011) Y. Jiao et al. SCIENCE
- Understanding the molecular-based mechanism of action of the tyrosine kinase inhibitor: sunitinib
- (2010) Alfredo Carrato Mena et al. ANTI-CANCER DRUGS
- A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer
- (2010) Andrew H. Ko et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Synergistic antitumor effect of TRAIL in combination with sunitinib in vitro and in vivo
- (2010) Wanjing Ding et al. CANCER LETTERS
- Survival Benefit With Proapoptotic Molecular and Pathologic Responses From Dual Targeting of Mammalian Target of Rapamycin and Epidermal Growth Factor Receptor in a Preclinical Model of Pancreatic Neuroendocrine Carcinogenesis
- (2010) Christopher W. Chiu et al. JOURNAL OF CLINICAL ONCOLOGY
- A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
- (2010) E. M. O'Reilly et al. ONCOLOGIST
- The Pathologic Classification of Neuroendocrine Tumors
- (2010) David S. Klimstra et al. PANCREAS
- Neuroendocrine Carcinomas of the Lung
- (2009) Cesar A. Moran et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Gemcitabine and oxaliplatin combination chemotherapy for metastatic well-differentiated neuroendocrine carcinomas
- (2009) Philippe A. Cassier et al. CANCER
- Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
- (2009) S. George et al. EUROPEAN JOURNAL OF CANCER
- Phase II Study of Sunitinib Administered in a Continuous Once-Daily Dosing Regimen in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
- (2009) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
- (2009) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Predicting Prognosis in Gastroentero-Pancreatic Neuroendocrine Tumors: An Overview and the Value of Ki-67 Immunostaining
- (2008) Mina Jamali et al. ENDOCRINE PATHOLOGY
- SU11248 (Sunitinib) Sensitizes Pancreatic Cancer to the Cytotoxic Effects of Ionizing Radiation
- (2008) Kyle C. Cuneo et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study
- (2008) James C. Yao et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors
- (2008) Matthew H. Kulke et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
- (2008) Jean-Philippe Spano et al. LANCET
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started